Bicara Therapeutics Inc. Net Fee Amt
Bicara Therapeutics Inc. (BCAX) had Net Fee Amt of $2.68 thousand as of 2026-08-10, per its S-8 filed 2026-08-11.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-11
- 2026-08-10: Net Fee Amt $2.68K.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-10 | $2.68K S-8 · filed 2026-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |